PD0332991 HCl
- Catalog NO.:A852586
- CAS No. : 827022-32-2
- Molecular Formula:C24H30ClN7O2
- Molecular Weight: 483.99
1. Please click the
![](/usr/uploads/3/201903/xunpan.png.png)
2. Click“Bulk Inquiry”to ask for quotations of other quantity.
3. The price does not include shipping and bank charges.
Product Details
CAS Number | 827022-32-2 | Appearance | Yellow powder |
Catalog Number | A852586 | MDL Number | MFCD22420809 |
Molecular Formula | C24H30ClN7O2 | Molecular Weight | 483.99 |
Boiling Point | Melting Point | ||
Flash Point | Density | ||
Synonyms | 6-acetyl-8-cyclopentyl-5-Methyl-2-(5-(piperazin-1-yl)pyridin-2-ylaMino)pyrido[2,3-d]pyriMidin-7(8H)-one hydrochloride;Palbociclib hydrochloride | ||
Storage Condition | Store in a tightly closed container,in a cool and dry place |
Safety
GHS Pictogram |
![]() |
||
Signal Word | Warning | UN Number | |
Hazard Statements | H302-H315-H319-H335 | Class | |
Precautionary Statements | P261-P305+P351+P338 | Packing Group |
Description
Palbociclib, also known as PD-0332991, is an orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression. Palbociclib, was approved on February 3, 2015 as a treatment (in combination with letrozole) for patients with estrogen receptor-positive advanced breast cancer. |